TABLE 1. Influenza vaccines — United States, 2024–25 influenza season*.
| Trade name (manufacturer) | Presentations | Age indication | μg HA (IIV3s and RIV3) or virus count (LAIV3) for each vaccine virus (per dose) | Route | Mercury (from thimerosal, if present), μg/0.5 mL |
|---|---|---|---|---|---|
| IIV3s (standard-dose, egg-based vaccines†) | |||||
| Afluria (Seqirus) |
0.5-mL PFS§ | ≥3 yrs§ | 15 μg/0.5 mL | IM¶ | —** |
| 5.0-mL MDV§ | ≥6 mos§ (needle
and syringe) 18 through 64 yrs (jet injector) |
7.5 μg/0.25
mL 15 μg/0.5 mL |
IM¶ | 24.5 | |
| Fluarix (GlaxoSmithKline) |
0.5-mL PFS | ≥6 mos | 15 μg/0.5 mL | IM¶ | — |
| FluLaval (GlaxoSmithKline) |
0.5-mL PFS | ≥6 mos | 15 μg/0.5 mL | IM¶ | — |
| Fluzone (Sanofi Pasteur) |
0.5-mL PFS†† | ≥6 mos†† | 15 μg/0.5 mL | IM¶ | — |
| 5.0-mL MDV†† | ≥6 mos†† | 7.5 μg/0.25
mL 15 μg/0.5 mL |
IM¶ | 25 | |
| ccIIV3 (standard-dose, cell culture-based vaccine) | |||||
| Flucelvax (Seqirus) |
0.5-mL PFS | ≥6 mos | 15 μg/0.5 mL | IM¶ | — |
| 5.0-mL MDV | ≥6 mos | 15 μg/0.5 mL | IM¶ | 25 | |
| HD-IIV3 (high-dose, egg-based vaccine†) | |||||
| Fluzone
High-Dose (Sanofi Pasteur) |
0.5-mL PFS | ≥65 yrs | 60 μg/0.5 mL | IM¶ | — |
| aIIV3 (standard-dose, egg-based vaccine† with MF59 adjuvant) | |||||
| Fluad (Seqirus) |
0.5-mL PFS | ≥65 yrs | 15 μg/0.5 mL | IM¶ | — |
| RIV3 (recombinant HA vaccine) | |||||
| Flublok (Sanofi Pasteur) |
0.5-mL PFS | ≥18 yrs | 45 μg/0.5 mL | IM¶ | — |
| LAIV3 (egg-based vaccine†) | |||||
| FluMist (AstraZeneca) |
0.2-mL prefilled single-use intranasal sprayer | 2 through 49 yrs | 106.5–7.5 fluorescent focus units/0.2 mL | NAS | — |
Abbreviations: ACIP = Advisory Committee on Immunization Practices; aIIV3 = adjuvanted inactivated influenza vaccine, trivalent; ccIIV3 = cell culture-based inactivated influenza vaccine, trivalent; HA = hemagglutinin; HD-IIV3 = high-dose inactivated influenza vaccine, trivalent; IIV3 = inactivated influenza vaccine, trivalent; IM = intramuscular; LAIV3 = live attenuated influenza vaccine, trivalent; MDV = multidose vial; NAS = intranasal; PFS = prefilled syringe; RIV3 = recombinant influenza vaccine, trivalent.
* Manufacturer package inserts and updated CDC and ACIP guidance should be consulted for additional information concerning, but not limited to, indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states. Availability and characteristics of specific products and presentations might change or differ from what is described in this table and in the text of this report.
† Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV3s and LAIV3, ACIP recommends that all persons aged ≥6 months with egg allergy should receive influenza vaccine and that any influenza vaccine (egg based or nonegg based) that is otherwise appropriate for the recipient’s age and health status can be used (see Persons with a History of Egg Allergy).
§ The approved dose volume for Afluria is 0.25 mL for children aged 6 through 35 months and 0.5 mL for persons aged ≥3 years. However, 0.25-mL prefilled syringes are no longer available. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a multidose vial.
¶ IM-administered influenza vaccines should be administered by needle and syringe only, except for the MDV presentation of Afluria, which can alternatively be given by the PharmaJet Stratis jet injector for persons aged 18 through 64 years only. For older children and adults, the recommended site for IM influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Additional specific guidance regarding site selection and needle length for IM administration is available in the General Best Practice Guidelines for Immunization available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.
** Not applicable.
†† Fluzone is approved for children aged 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL prefilled syringes are no longer available. If a prefilled syringe of Fluzone is used for a child in this age group, the dose volume will be 0.5 mL per dose.